← Leaderboards
Kevin Jon Williams
Thomas Jefferson University
$8,236,019
Attributed
$8,236,019
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,236,019 · 10
By mechanism
R01$7,773,518 · 8
R21$462,501 · 1
P50$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Elias G Argyris$497,848
- Barry J. Goldstein$8,171,579
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMolecularReceptorEnzymesCell SurfaceSignal TransductionIn VivoHeparan Sulfate ProteoglycanBaseHepatocytePlasmaParticipantLaboratoriesCatabolismLow-Density LipoproteinsLipoproteinsPublishingMediatingCellsPathway InteractionsAtherosclerosisNon-Insulin-Dependent Diabetes MellitusBinding (Molecular Function)Hepatic
Grant awards (27)
Sulfatase-2: Key mediator of atherogenic postprandial dyslipoproteinemia$390,000
R01 · FY2017 · DK · contact PI
Sulfatase-2: Key mediator of atherogenic postprandial dyslipoproteinemia$390,000
R01 · FY2016 · DK · contact PI
Sulfatase-2: Key mediator of atherogenic postprandial dyslipoproteinemia$390,000
R01 · FY2015 · DK · contact PI
Sulfatase-2: Key mediator of atherogenic postprandial dyslipoproteinemia$390,000
R01 · FY2014 · DK · contact PI
Sulfatase-2: Key mediator of atherogenic postprandial dyslipoproteinemia$387,500
R01 · FY2013 · DK · contact PI
HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemia$371,250
R01 · FY2012 · HL · contact PI
Screens for novel compounds to correct diabetic postprandial dyslipidemia$375,000
R01 · FY2011 · HL · contact PI
HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemia$375,000
R01 · FY2011 · HL · contact PI
HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemia$375,000
R01 · FY2010 · HL · contact PI
Screens for novel compounds to correct diabetic postprandial dyslipidemia$375,000
R01 · FY2010 · HL · contact PI
Screens for novel compounds to correct diabetic postprandial dyslipidemia$375,000
R01 · FY2009 · HL · contact PI
HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemia$375,000
R01 · FY2009 · HL · contact PI
Protein-Tyrosine Phosphatases and Insulin Action$258,176
R01 · FY2009 · DK · contact PI
Protein-Tyrosine Phosphatases and Insulin Action$71,688
R01 · FY2009 · DK · contact PI
Protein-Tyrosine Phosphatases and Insulin Action$338,469
R01 · FY2008 · DK · contact PI
Endocytic Trafficking Motifs in Syndecan & LDL receptor$189,294
R01 · FY2008 · HL · contact PI
Endocytic Trafficking Motifs in Syndecan & LDL receptor$106,539
R01 · FY2008 · HL · contact PI
Adiponectin Improves Vascular Function In High Glucose$332,812
R01 · FY2007 · DK · contact PI
Adiponectin: Vascular Responses and Signaling Mechanisms$332,048
R01 · FY2007 · DK · contact PI
Endocytic Trafficking Motifs in Syndecan & LDL receptor$295,832
R01 · FY2007 · HL · contact PI
Endocytic Trafficking Motifs in Syndecan & LDL receptor$304,668
R01 · FY2006 · HL · contact PI
Transmigration of HIV-1-infected cells in NeuroAIDS$228,501
R21 · FY2006 · MH · contact PI
Endocytic Trafficking Motifs in Syndecan &LDL receptor$337,103
R01 · FY2005 · HL
Transmigration of HIV-1-infected cells in NeuroAIDS$234,000
R21 · FY2005 · MH
Small leucine rich proteoglycans and atherogenesis$0
P50 · FY2002 · HL
ENDOTHELIAL MATRIX IN ATHEROGENESIS$323,381
R01 · FY2001 · HL
ENDOTHELIAL MATRIX IN ATHEROGENESIS$314,758
R01 · FY2000 · HL